LORAZEPAM AS AN ADJUNCT TO ANTIEMETIC THERAPY WITH HALOPERIDOL IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY

Australian and New Zealand Journal of Medicine

Volumn 13, Issue 1, 1983, Pages 53-56

  FRIEDLANDER, M L ^a   KEARSLEY, J H ^a   SIMS, K ^b   COATES, A ^a   HEDLEY, D ^a   RAGHAVAN, D ^a   FOX, R M ^c   TATTERSALL, M H N ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

antiemetic; haloperidol; lorazepam; Pilot study; quality of life

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HALOPERIDOL; LORAZEPAM; VINBLASTINE;

ADVERSE DRUG REACTION; AGITATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG THERAPY; GASTROINTESTINAL TOXICITY; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; MOUTH; NAUSEA; ORAL DRUG ADMINISTRATION; PREVENTION; THERAPY; VOMITING; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HALOPERIDOL; HUMANS; LORAZEPAM; MALE; NAUSEA; PILOT PROJECTS; VOMITING;

EID: 0020554039     PISSN: 00048291     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1983.tb04550.x     Document Type: Article

References (8)

1. Cis‐diamminedichloroplatinum (II)
2. Management of nausea and vomiting in the cancer patient
3. Antiemetic effect of intravenous diazepam in patients receiving cis‐diamminedichloroplatinum (II): A pilot study
4. Physiology and pharmacology of vomiting
5. Nausea, vomiting and cancer treatment
6. Clinical pharmokinetics of lorazepam. Absorption and disposition of oral “C‐lorazepam”
7. Intravenous lorazepam to prevent nausea and vomiting associated with cancer chemotherapy
8. Oral lorazepam to improve tolerance of cytotoxic therapy